Pmv Pharmaceuticals Inc (PMVP) - Net Assets
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has net assets worth $71.50 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.07 Million) and total liabilities ($10.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PMVP PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $71.50 Million |
| % of Total Assets | 87.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -66.06% |
| 10-Year Change | N/A |
| Growth Volatility | 10.89 |
Pmv Pharmaceuticals Inc - Net Assets Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Pmv Pharmaceuticals Inc worth.
Annual Net Assets for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Pmv Pharmaceuticals Inc from 2018 to 2025. Also explore PMVP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $104.71 Million | -40.53% |
| 2024-12-31 | $176.08 Million | -21.98% |
| 2023-12-31 | $225.69 Million | -8.27% |
| 2022-12-31 | $246.03 Million | -20.27% |
| 2021-12-31 | $308.56 Million | -14.08% |
| 2020-12-31 | $359.12 Million | +609.58% |
| 2019-12-31 | $-70.47 Million | -52.74% |
| 2018-12-31 | $-46.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pmv Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39636600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $84.00K | 0.08% |
| Other Components | $551.08 Million | 526.28% |
| Total Equity | $104.71 Million | 100.00% |
Pmv Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hainan Airlines Co Ltd B
SHG:900945
|
$73.52 Million |
|
Kumpulan Perangsang Selangor
KLSE:5843
|
$73.53 Million |
|
Konka Group Co Ltd
SHE:200016
|
$73.54 Million |
|
Broadway Financial Corporation
NASDAQ:BYFC
|
$73.55 Million |
|
5E Advanced Materials Inc
AU:5EA
|
$73.44 Million |
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
$73.42 Million |
|
SG&G Corporation
KQ:040610
|
$73.41 Million |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
$73.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pmv Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 176,080,000 to 104,712,000, a change of -71,368,000 (-40.5%).
- Net loss of 77,742,000 reduced equity.
- Other comprehensive income decreased equity by 55,000.
- Other factors increased equity by 6,429,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-77.74 Million | -74.24% |
| Other Comprehensive Income | $-55.00K | -0.05% |
| Other Changes | $6.43 Million | +6.14% |
| Total Change | $- | -40.53% |
Book Value vs Market Value Analysis
This analysis compares Pmv Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-15.26 | $1.46 | x |
| 2019-12-31 | $-1.64 | $1.46 | x |
| 2020-12-31 | $8.02 | $1.46 | x |
| 2021-12-31 | $6.84 | $1.46 | x |
| 2022-12-31 | $5.40 | $1.46 | x |
| 2023-12-31 | $4.70 | $1.46 | x |
| 2024-12-31 | $3.41 | $1.46 | x |
| 2025-12-31 | $1.99 | $1.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pmv Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-74.24%) is below the historical average (-24.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.92 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.30 Million |
| 2020 | -9.59% | 0.00% | 0.00x | 1.02x | $-70.35 Million |
| 2021 | -18.75% | 0.00% | 0.00x | 1.07x | $-88.70 Million |
| 2022 | -29.80% | 0.00% | 0.00x | 1.10x | $-97.92 Million |
| 2023 | -30.56% | 0.00% | 0.00x | 1.12x | $-91.53 Million |
| 2024 | -33.34% | 0.00% | 0.00x | 1.09x | $-76.32 Million |
| 2025 | -74.24% | 0.00% | 0.00x | 1.11x | $-88.21 Million |
Industry Comparison
This section compares Pmv Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pmv Pharmaceuticals Inc (PMVP) | $71.50 Million | 0.00% | 0.15x | $73.50 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more